Work

Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600–mutant melanoma

Year: 2016

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw379.32

Authors: J.J. Grob, C. Robert, G.V. Long, D. Stroyakovskiy, E. Levchenko, V. Chiarion-Sileni, K. Flaherty, P. Nathan, A. Ribas, M. Davies, J. Zhang, L. Chen, B. Mookerjee, S. Redhu, D. Schadendorf

Institutions: Aix-Marseille Université, Institut Gustave Roussy, Fondation Gustave Roussy, The University of Sydney, Melanoma Institute Australia, Moscow City Oncology Hospital №62, Institute of Oncology NN Petrov, Istituto Oncologico Veneto, Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Mount Vernon Cancer Centre, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, Novartis (United States), Essen University Hospital

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Incyte, Genentech, Kite Pharma

OpenAlex ID: W2589107802

FWCI: 0.151

Cites:

Cited by: 1

Related to: 10